Atogepant, an oral calcitonin gene-related peptide (CGRP) antagonist, was shown to be effective and safe for migraine prevention. This adds an additional CGRP antagonist to the growing arsenal of such medications, both oral and parenteral, for both prevention and treatment of migraine.
Primary headaches, especially migraines, are a common problem for adults and children who present to the emergency department. Migraine headaches have been challenging to diagnose, especially in the pediatric population.
Patients with migraine who have an insufficient response to acute treatment medications, including triptans, risk developing medication overuse headache (MOH). The most successful treatment for MOH is withdrawal of the offending acute pain medications combined with early use of a migraine preventative medication.